دورية أكاديمية
Development of Robust Freeze-Drying Process for Long-Term Stability of rVSV-SARS-CoV-2 Vaccine.
العنوان: | Development of Robust Freeze-Drying Process for Long-Term Stability of rVSV-SARS-CoV-2 Vaccine. |
---|---|
المؤلفون: | Khan MDFH; Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H2X 1Y4, Canada., Youssef M; Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H2X 1Y4, Canada., Nesdoly S; Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H2X 1Y4, Canada., Kamen AA; Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H2X 1Y4, Canada. |
المصدر: | Viruses [Viruses] 2024 Jun 11; Vol. 16 (6). Date of Electronic Publication: 2024 Jun 11. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101509722 Publication Model: Electronic Cited Medium: Internet ISSN: 1999-4915 (Electronic) Linking ISSN: 19994915 NLM ISO Abbreviation: Viruses Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
مواضيع طبية MeSH: | Freeze Drying*/methods , SARS-CoV-2*/immunology , SARS-CoV-2*/chemistry , COVID-19 Vaccines*/immunology , COVID-19 Vaccines*/chemistry , Spike Glycoprotein, Coronavirus*/chemistry , Spike Glycoprotein, Coronavirus*/immunology , Cryoprotective Agents*/chemistry , Cryoprotective Agents*/pharmacology, Trehalose/chemistry ; COVID-19/prevention & control ; COVID-19/virology ; Animals ; Humans ; Mannitol/chemistry ; Sucrose/chemistry ; Vero Cells ; Chlorocebus aethiops ; Sorbitol/chemistry ; Drug Stability ; Histidine/chemistry ; Vesicular stomatitis Indiana virus/genetics ; Vaccines, Synthetic/chemistry ; Vaccines, Synthetic/immunology |
مستخلص: | The thermostability of vaccines, particularly enveloped viral vectored vaccines, remains a challenge to their delivery wherever needed. The freeze-drying of viral vectored vaccines is a promising approach but remains challenging due to the water removal process from the outer and inner parts of the virus. In the case of enveloped viruses, freeze-drying induces increased stress on the envelope, which often leads to the inactivation of the virus. In this study, we designed a method to freeze-dry a recombinant vesicular stomatitis virus (VSV) expressing the SARS-CoV-2 spike glycoprotein. Since the envelope of VSV is composed of 50% lipids and 50% protein, the formulation study focused on both the protein and lipid portions of the vector. Formulations were prepared primarily using sucrose, trehalose, and sorbitol as cryoprotectants; mannitol as a lyoprotectant; and histidine as a buffer. Initially, the infectivity of rVSV-SARS-CoV-2 and the cake stability were investigated at different final moisture content levels. High recovery of the infectious viral titer (~0.5 to 1 log loss) was found at 3-6% moisture content, with no deterioration in the freeze-dried cakes. To further minimize infectious viral titer loss, the composition and concentration of the excipients were studied. An increase from 5 to 10% in both the cryoprotectants and lyoprotectant, together with the addition of 0.5% gelatin, resulted in the improved recovery of the infectious virus titer and stable cake formation. Moreover, the secondary drying temperature of the freeze-drying process showed a significant impact on the infectivity of rVSV-SARS-CoV-2. The infectivity of the vector declined drastically when the temperature was raised above 20 °C. Throughout a long-term stability study, formulations containing 10% sugar (sucrose/trehalose), 10% mannitol, 0.5% gelatin, and 10 mM histidine showed satisfactory stability for six months at 2-8 °C. The development of this freeze-drying process and the optimized formulation minimize the need for a costly cold chain distribution system. |
References: | Biotechnol Bioeng. 2021 Jul;118(7):2649-2659. (PMID: 33837958) Pharmaceutics. 2022 Feb 17;14(2):. (PMID: 35214162) Appl Microbiol. 1970 Dec;20(6):935-8. (PMID: 5492441) BMC Public Health. 2019 Nov 1;19(1):1433. (PMID: 31675948) Vaccine. 2015 Oct 13;33(42):5507-5519. (PMID: 26364685) Dev Biol Stand. 1996;87:97-101. (PMID: 8854006) Bull Pan Am Health Organ. 1989;23(3):299-305. (PMID: 2571379) J Microbiol Methods. 2006 Aug;66(2):183-93. (PMID: 16632005) Bull Exp Biol Med. 2018 May;165(1):52-56. (PMID: 29796807) J Clin Microbiol. 1976 Jul;4(1):1-5. (PMID: 182713) J Pharm Sci. 2018 Aug;107(8):2070-2078. (PMID: 29709487) Vaccines (Basel). 2023 Dec 29;12(1):. (PMID: 38250854) Crit Rev Ther Drug Carrier Syst. 1999;16(1):1-83. (PMID: 10099898) PLoS Pathog. 2021 Dec 16;17(12):e1010092. (PMID: 34914812) Poult Sci. 2010 Jun;89(6):1167-70. (PMID: 20460663) J Clin Microbiol. 1983 Sep;18(3):658-62. (PMID: 6313747) J Virol. 2014 Nov;88(22):13189-200. (PMID: 25187542) J Pharm Sci. 2005 Jul;94(7):1427-44. (PMID: 15920775) J Chromatogr A. 1995 Jun 23;705(1):115-27. (PMID: 7620565) J Pharm Sci. 2021 Feb;110(2):627-634. (PMID: 33242452) Appl Microbiol. 1970 Nov;20(5):723-6. (PMID: 4320863) J Gen Virol. 1972 Dec;17(3):281-8. (PMID: 4346651) Signal Transduct Target Ther. 2022 May 3;7(1):146. (PMID: 35504917) Biotechnol Prog. 2004 Jul-Aug;20(4):1113-20. (PMID: 15296437) Biologicals. 1998 Dec;26(4):309-16. (PMID: 10403034) Gene Ther. 2001 Sep;8(17):1281-90. (PMID: 11571564) J Pharm Sci. 1998 Dec;87(12):1615-21. (PMID: 10189276) Vaccine. 2019 Oct 16;37(44):6696-6706. (PMID: 31548012) Int J Pharm. 2019 Apr 20;561:66-73. (PMID: 30825554) Vaccine. 1988 Feb;6(1):12-3. (PMID: 3354252) Methods Mol Biol. 2022;2452:131-146. (PMID: 35554905) Vaccine. 2017 Apr 19;35(17):2217-2223. (PMID: 27670076) Vaccine. 2019 Nov 8;37(47):6996-7002. (PMID: 31288997) Arch Gesamte Virusforsch. 1970;29(2):257-62. (PMID: 5464034) Vaccines (Basel). 2023 Apr 14;11(4):. (PMID: 37112753) NPJ Vaccines. 2022 Jul 25;7(1):82. (PMID: 35879345) Arch Biochem Biophys. 1994 May 15;311(1):180-90. (PMID: 8185315) Hum Vaccin Immunother. 2019;15(10):2269-2285. (PMID: 31368826) |
معلومات مُعتمدة: | RGPIN-2021-02691 Natural Sciences and Engineering Council of Canada; CRC-240394 Canada Research Chair |
فهرسة مساهمة: | Keywords: COVID-19; CPPs; CQAs; VSV; enveloped viral vector vaccine; freeze-drying; rVSV-SARS-CoV-2; solid formulation; stability; vesicular stomatitis virus; viral vaccine bioprocess |
المشرفين على المادة: | 0 (COVID-19 Vaccines) 0 (Spike Glycoprotein, Coronavirus) 0 (Cryoprotective Agents) B8WCK70T7I (Trehalose) 3OWL53L36A (Mannitol) 0 (spike protein, SARS-CoV-2) 57-50-1 (Sucrose) 506T60A25R (Sorbitol) 4QD397987E (Histidine) 0 (Vaccines, Synthetic) |
تواريخ الأحداث: | Date Created: 20240627 Date Completed: 20240627 Latest Revision: 20240629 |
رمز التحديث: | 20240629 |
مُعرف محوري في PubMed: | PMC11209311 |
DOI: | 10.3390/v16060942 |
PMID: | 38932234 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!